OrganiGram Capex To Revenue vs Cost Of Revenue Analysis

OGI Stock

USD 1.48 0.03 2.07%

OrganiGram Holdings financial indicator trend analysis is much more than just breaking down OrganiGram Holdings prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether OrganiGram Holdings is a good investment. Please check the relationship between OrganiGram Holdings Capex To Revenue and its Cost Of Revenue accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in OrganiGram Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

For more detail on how to invest in OrganiGram Stock please use our How to Invest in OrganiGram Holdings guide.

Capex To Revenue vs Cost Of Revenue

Capex To Revenue vs Cost Of Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of OrganiGram Holdings Capex To Revenue account and Cost Of Revenue. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between OrganiGram Holdings' Capex To Revenue and Cost Of Revenue is 0.53. Overlapping area represents the amount of variation of Capex To Revenue that can explain the historical movement of Cost Of Revenue in the same time period over historical financial statements of OrganiGram Holdings, assuming nothing else is changed. The correlation between historical values of OrganiGram Holdings' Capex To Revenue and Cost Of Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capex To Revenue of OrganiGram Holdings are associated (or correlated) with its Cost Of Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cost Of Revenue has no effect on the direction of Capex To Revenue i.e., OrganiGram Holdings' Capex To Revenue and Cost Of Revenue go up and down completely randomly.

Correlation Coefficient

0.53

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Capex To Revenue

The ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets.

Cost Of Revenue

Cost of Revenue is found on OrganiGram Holdings income statement and represents the costs associated with goods and services OrganiGram Holdings provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Most indicators from OrganiGram Holdings' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into OrganiGram Holdings current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in OrganiGram Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

For more detail on how to invest in OrganiGram Stock please use our How to Invest in OrganiGram Holdings guide.As of now, OrganiGram Holdings' Selling General Administrative is increasing as compared to previous years. The OrganiGram Holdings' current Enterprise Value Over EBITDA is estimated to increase to 31.81, while Discontinued Operations is projected to decrease to (35.9 K).

	2023	2024 (projected)
Reconciled Depreciation	28.6M	16.1M
Interest Income	11.8M	12.4M

Reconciled Depreciation Interest Income

OrganiGram Holdings fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Total Current Assets	Property Plant And Equipment Net	Accounts Payable	Common Stock Total Equity	Non Current Liabilities Total	Property Plant And Equipment Gross	Common Stock	Short Long Term Debt Total	Net Tangible Assets	Long Term Debt	Short Term Investments	Long Term Debt Total
Total Assets		0.26	0.92	0.99	-0.26	-0.55	0.93	0.98	0.61	0.81	0.8	0.74	0.78	0.8	0.97	0.97	0.89	0.86	0.55	0.81	0.76	0.34	0.99	0.3	0.65	0.75
Other Current Liab	0.26		0.34	0.35	-0.85	-0.22	0.39	0.27	0.48	0.24	0.38	0.3	0.12	-0.16	0.23	0.13	0.39	0.13	-0.37	0.31	0.29	-0.59	0.31	-0.61	0.11	0.01
Total Current Liabilities	0.92	0.34		0.92	-0.32	-0.49	0.85	0.95	0.54	0.55	0.84	0.68	0.68	0.68	0.84	0.92	0.98	0.8	0.36	0.73	0.71	0.23	0.91	0.19	0.32	0.59
Total Stockholder Equity	0.99	0.35	0.92		-0.39	-0.61	0.92	0.98	0.69	0.78	0.85	0.77	0.77	0.7	0.95	0.94	0.89	0.87	0.42	0.82	0.81	0.2	0.99	0.16	0.63	0.68
Net Debt	-0.26	-0.85	-0.32	-0.39		0.52	-0.32	-0.3	-0.7	-0.15	-0.54	-0.47	-0.26	0.3	-0.21	-0.14	-0.35	-0.3	0.57	-0.29	-0.51	0.79	-0.37	0.81	-0.12	0.09
Retained Earnings	-0.55	-0.22	-0.49	-0.61	0.52		-0.49	-0.53	-0.68	-0.3	-0.85	-0.94	-0.86	-0.15	-0.55	-0.45	-0.5	-0.85	0.14	-0.69	-0.94	0.23	-0.64	0.26	-0.39	-0.41
Cash	0.93	0.39	0.85	0.92	-0.32	-0.49		0.87	0.57	0.82	0.75	0.7	0.77	0.77	0.96	0.84	0.85	0.75	0.55	0.77	0.7	0.32	0.91	0.28	0.62	0.85
Non Current Assets Total	0.98	0.27	0.95	0.98	-0.3	-0.53	0.87		0.63	0.74	0.83	0.71	0.72	0.74	0.91	0.98	0.9	0.85	0.46	0.75	0.76	0.27	0.98	0.23	0.57	0.63
Non Currrent Assets Other	0.61	0.48	0.54	0.69	-0.7	-0.68	0.57	0.63		0.5	0.72	0.66	0.53	0.11	0.54	0.51	0.47	0.6	-0.14	0.57	0.71	-0.35	0.67	-0.38	0.48	0.24
Cash And Short Term Investments	0.81	0.24	0.55	0.78	-0.15	-0.3	0.82	0.74	0.5		0.46	0.5	0.58	0.75	0.85	0.74	0.5	0.58	0.66	0.62	0.52	0.38	0.78	0.35	0.93	0.73
Net Receivables	0.8	0.38	0.84	0.85	-0.54	-0.85	0.75	0.83	0.72	0.46		0.94	0.87	0.42	0.74	0.76	0.83	0.92	0.05	0.77	0.95	-0.07	0.86	-0.11	0.37	0.51
Common Stock Shares Outstanding	0.74	0.3	0.68	0.77	-0.47	-0.94	0.7	0.71	0.66	0.5	0.94		0.95	0.41	0.74	0.66	0.69	0.95	0.09	0.82	0.99	-0.04	0.81	-0.08	0.51	0.59
Other Stockholder Equity	0.78	0.12	0.68	0.77	-0.26	-0.86	0.77	0.72	0.53	0.58	0.87	0.95		0.6	0.82	0.7	0.69	0.94	0.33	0.8	0.93	0.22	0.82	0.18	0.56	0.78
Total Liab	0.8	-0.16	0.68	0.7	0.3	-0.15	0.77	0.74	0.11	0.75	0.42	0.41	0.6		0.83	0.83	0.66	0.6	0.91	0.55	0.4	0.81	0.72	0.78	0.57	0.84
Total Current Assets	0.97	0.23	0.84	0.95	-0.21	-0.55	0.96	0.91	0.54	0.85	0.74	0.74	0.82	0.83		0.9	0.83	0.84	0.62	0.84	0.75	0.4	0.95	0.36	0.72	0.86
Property Plant And Equipment Net	0.97	0.13	0.92	0.94	-0.14	-0.45	0.84	0.98	0.51	0.74	0.76	0.66	0.7	0.83	0.9		0.87	0.83	0.57	0.7	0.69	0.4	0.95	0.37	0.57	0.64
Accounts Payable	0.89	0.39	0.98	0.89	-0.35	-0.5	0.85	0.9	0.47	0.5	0.83	0.69	0.69	0.66	0.83	0.87		0.78	0.33	0.74	0.7	0.2	0.88	0.16	0.26	0.6
Common Stock Total Equity	0.86	0.13	0.8	0.87	-0.3	-0.85	0.75	0.85	0.6	0.58	0.92	0.95	0.94	0.6	0.84	0.83	0.78		0.29	0.83	0.96	0.16	0.91	0.12	0.56	0.64
Non Current Liabilities Total	0.55	-0.37	0.36	0.42	0.57	0.14	0.55	0.46	-0.14	0.66	0.05	0.09	0.33	0.91	0.62	0.57	0.33	0.29		0.32	0.07	0.93	0.43	0.92	0.54	0.76
Property Plant And Equipment Gross	0.81	0.31	0.73	0.82	-0.29	-0.69	0.77	0.75	0.57	0.62	0.77	0.82	0.8	0.55	0.84	0.7	0.74	0.83	0.32		0.78	0.18	0.82	0.14	0.58	0.67
Common Stock	0.76	0.29	0.71	0.81	-0.51	-0.94	0.7	0.76	0.71	0.52	0.95	0.99	0.93	0.4	0.75	0.69	0.7	0.96	0.07	0.78		-0.08	0.84	-0.12	0.52	0.55
Short Long Term Debt Total	0.34	-0.59	0.23	0.2	0.79	0.23	0.32	0.27	-0.35	0.38	-0.07	-0.04	0.22	0.81	0.4	0.4	0.2	0.16	0.93	0.18	-0.08		0.21	1.0	0.28	0.63
Net Tangible Assets	0.99	0.31	0.91	0.99	-0.37	-0.64	0.91	0.98	0.67	0.78	0.86	0.81	0.82	0.72	0.95	0.95	0.88	0.91	0.43	0.82	0.84	0.21		0.17	0.65	0.69
Long Term Debt	0.3	-0.61	0.19	0.16	0.81	0.26	0.28	0.23	-0.38	0.35	-0.11	-0.08	0.18	0.78	0.36	0.37	0.16	0.12	0.92	0.14	-0.12	1.0	0.17		0.25	0.6
Short Term Investments	0.65	0.11	0.32	0.63	-0.12	-0.39	0.62	0.57	0.48	0.93	0.37	0.51	0.56	0.57	0.72	0.57	0.26	0.56	0.54	0.58	0.52	0.28	0.65	0.25		0.62
Long Term Debt Total	0.75	0.01	0.59	0.68	0.09	-0.41	0.85	0.63	0.24	0.73	0.51	0.59	0.78	0.84	0.86	0.64	0.6	0.64	0.76	0.67	0.55	0.63	0.69	0.6	0.62

Click cells to compare fundamentals

OrganiGram Holdings Account Relationship Matchups

OrganiGram Holdings fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	417.6M	554.0M	577.1M	298.5M	343.2M	251.2M
Other Current Liab	(11.6M)	6.3M	12.0M	2.3M	2.6M	2.1M
Total Current Liabilities	29.1M	26.3M	55.3M	22.4M	25.8M	18.3M
Total Stockholder Equity	299.5M	479.8M	508.1M	271.6M	312.4M	202.3M
Net Debt	79.1M	(50.4M)	(65.2M)	(30.2M)	(27.1M)	(25.8M)
Retained Earnings	(144.9M)	(275.6M)	(289.9M)	(538.5M)	(484.7M)	(460.4M)
Cash	24.6M	55.4M	68.5M	33.9M	38.9M	27.4M
Non Current Assets Total	247.4M	293.4M	355.5M	142.5M	163.9M	144.2M
Non Currrent Assets Other	8.0M	31.1M	32.4M	19.1M	22.0M	12.7M
Cash And Short Term Investments	74.7M	183.8M	98.9M	33.9M	38.9M	58.5M
Net Receivables	17.0M	21.0M	43.9M	27.5M	31.6M	33.2M
Common Stock Shares Outstanding	43.2M	64.0M	77.2M	81.3M	93.5M	98.2M
Liabilities And Stockholders Equity	417.6M	554.0M	577.1M	298.5M	343.2M	251.2M
Other Stockholder Equity	23.7M	24.7M	28.3M	33.2M	38.2M	40.1M
Total Liab	118.1M	74.2M	69.0M	26.8M	30.9M	48.9M
Total Current Assets	170.2M	260.6M	221.6M	156.0M	179.4M	119.0M
Property Plant And Equipment Net	247.4M	235.9M	259.8M	99.0M	113.9M	135.1M
Accounts Payable	17.5M	19.0M	40.9M	20.0M	23.0M	15.8M
Non Current Liabilities Total	89.0M	47.9M	13.8M	4.4M	5.1M	4.8M
Accumulated Other Comprehensive Income	23.8M	24.6M	28.3M	33.2M	38.2M	40.1M
Common Stock	420.7M	730.8M	769.7M	776.9M	893.4M	938.1M
Short Long Term Debt Total	103.7M	5.0M	3.4M	3.7M	3.3M	3.2M
Other Liab	231K	43.1M	11.4M	771K	886.7K	842.3K
Net Tangible Assets	297.8M	462.8M	451.8M	261.0M	300.1M	258.4M
Other Assets	8.7M	35.4M	33.1M	1.0	1.15	1.09
Long Term Debt	46.1M	103.7M	230K	155K	178.3K	169.3K
Short Term Investments	380K	50.1M	128.5M	30.4M	35.0M	46.6M
Inventory	71.8M	48.8M	68.3M	81.0M	93.1M	56.5M
Other Current Assets	6.7M	7.0M	10.6M	13.7M	15.8M	10.0M
Deferred Long Term Liab	698K	7K	30K	391K	449.7K	354.3K
Long Term Investments	11.1M	7.0M	6.1M	7.1M	8.1M	4.3M
Short Long Term Debt	421K	3.5M	11.6M	80K	92K	87.4K
Short Term Debt	11.6M	1.1M	996K	76K	87.4K	83.0K
Intangible Assets	1.8M	2.7M	14.3M	10.6M	12.2M	12.8M

Currently Active Assets on Macroaxis

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America
S	SentinelOne
WD	Walker Dunlop

When determining whether OrganiGram Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of OrganiGram Holdings' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Organigram Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Organigram Holdings Stock:

How To Invest In OrganiGram

Details

Is OrganiGram Stock a good investment?

Details

What is OrganiGram Holdings' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in OrganiGram Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

For more detail on how to invest in OrganiGram Stock please use our How to Invest in OrganiGram Holdings guide.

You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of OrganiGram Holdings. If investors know OrganiGram will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about OrganiGram Holdings listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.80)

Revenue Per Share

1.835

Quarterly Revenue Growth

(0.14)

Return On Assets

(0.06)

Return On Equity

(0.55)

The market value of OrganiGram Holdings is measured differently than its book value, which is the value of OrganiGram that is recorded on the company's balance sheet. Investors also form their own opinion of OrganiGram Holdings' value that differs from its market value or its book value, called intrinsic value, which is OrganiGram Holdings' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because OrganiGram Holdings' market value can be influenced by many factors that don't directly affect OrganiGram Holdings' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between OrganiGram Holdings' value and its price as these two are different measures arrived at by different means. Investors typically determine if OrganiGram Holdings is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, OrganiGram Holdings' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

OrganiGram Capex To Revenue vs Cost Of Revenue Analysis

Capex To Revenue vs Cost Of Revenue

Capex To Revenue vs Cost Of Revenue Correlation Analysis

Correlation Coefficient

Capex To Revenue

Cost Of Revenue

OrganiGram Holdings fundamental ratios Correlations

OrganiGram Holdings Account Relationship Matchups

High Positive Relationship

High Negative Relationship

OrganiGram Holdings fundamental ratios Accounts

Currently Active Assets on Macroaxis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Long Term Debt	+ 1.0	Short Long Term Debt Total
Total Stockholder Equity	+ 0.99	Total Assets
Net Tangible Assets	+ 0.99	Total Assets
Net Tangible Assets	+ 0.99	Total Stockholder Equity
Common Stock	+ 0.99	Common Stock Shares Outstanding
Non Current Assets Total	+ 0.98	Total Assets

Common Stock	- 0.94	Retained Earnings
Common Stock Shares Outstanding	- 0.94	Retained Earnings
Other Stockholder Equity	- 0.86	Retained Earnings
Common Stock Total Equity	- 0.85	Retained Earnings
Net Receivables	- 0.85	Retained Earnings
Net Debt	- 0.85	Other Current Liab